The US District Court for the District of New Jersey dismisses antitrust class action against two pharma producers regarding an agreement because no reverse payment with cash was involved to keep the rival off the market (GlaxoSmithKline / Teva)

KEYWORDS
Reference

US District Court for the District of New Jersey, GSK / Teva, No. 12-cv-995, 24 January 2014

U.S. District Court holds that Actavis requires monetary payments for antitrust scrutiny to be applicable* On January 24, 2014 U.S. District Judge William H. Walls dismissed an antitrust class action against GlaxoSmithKline LLC (“GSK”) and Teva Pharmaceutical Industries Ltd. (“Teva”) regarding their agreement to postpone the production of a generic epilepsy and bipolar disorder drug since no reverse payment with cash was involved to keep the rival off the market. According to Actavis antitrust rules therefore were not applied to the case at hand. In 2002 Teva filed an application to produce a generic version of the Lamictal drug to the U.S. Food and Drug Administration. GSK in turn sued

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • DLA Piper Weiss-Tessbach (Vienna)
    Austria 26 contributions 7358 visits

Quotation

Nicole Daniel, The US District Court for the District of New Jersey dismisses antitrust class action against two pharma producers regarding an agreement because no reverse payment with cash was involved to keep the rival off the market (GlaxoSmithKline / Teva), 24 January 2014, e-Competitions Pay-for-delay agreements, Art. N° 64811

Visites 232

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues